top of page
The Sound of Evolution
Ofatumumab
Mechanism of action:
Ofatumumab is a first-generation anti-CD20 IgG1 monoclonal antibody. The target of ofatumumab is the CD20 antigen on the surface of B cells. After ofatumumab binds to CD20, its Fc region recruits complement protein C1q, initiating the complement cascade and forming the membrane attack complex (MAC), which leads to B cell membrane rupture and death.
Reference(s):
1. Lin TS et al. (2010). Ofatumumab: a novel monoclonal anti-CD20 antibody. Pharmgenomics Pers Med.
2. Glennie MJ et al. (2007). Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol.
3. Ryman JT et al. (2017). Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacometrics Syst Pharmacol.
bottom of page